PolyMedix to Review Interim Results From Multinational Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic
PolyMedix (OTC: PYMX) has scheduled a conference call and webcast for Wednesday, December 7 at 9:00 AM Eastern Time. At that time, management will review the results of the interim analysis from the ongoing Phase 2 clinical study with PMX-30063, defensin-mimetic antibiotic in treating patients with Staph Acute Bacterial Skin and Skin Structure Infections. This is the first clinical study ever conducted in patients with Staph infections with this new class of antibiotic – a defensin-mimetic.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.